HC Wainwright Estimates Envoy Medical Q1 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Envoy Medical in a research report issued to clients and investors on Tuesday, March 31st. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.30) EPS.

A number of other brokerages also recently weighed in on COCH. Zacks Research upgraded Envoy Medical to a “hold” rating in a report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Envoy Medical in a report on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Envoy Medical presently has an average rating of “Hold” and an average target price of $6.00.

Envoy Medical Stock Performance

Shares of NASDAQ COCH opened at $0.75 on Thursday. Envoy Medical has a one year low of $0.36 and a one year high of $1.91. The firm has a market capitalization of $57.47 million, a PE ratio of -0.61 and a beta of 2.07. The business has a 50-day moving average price of $0.68 and a two-hundred day moving average price of $0.76.

Envoy Medical (NASDAQ:COCH) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.03 million.

Hedge Funds Weigh In On Envoy Medical

Several institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. bought a new stake in shares of Envoy Medical during the 3rd quarter worth about $60,000. Geode Capital Management LLC increased its holdings in shares of Envoy Medical by 111.3% during the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock valued at $65,000 after acquiring an additional 51,813 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in shares of Envoy Medical in the 1st quarter valued at approximately $276,000. 8.59% of the stock is currently owned by institutional investors.

Insider Transactions at Envoy Medical

In other Envoy Medical news, Director Susan Kantor bought 96,150 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was bought at an average cost of $0.40 per share, with a total value of $38,460.00. Following the completion of the transaction, the director directly owned 174,037 shares of the company’s stock, valued at approximately $69,614.80. The trade was a 123.45% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mona Chetan Patel purchased 312,500 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were acquired at an average price of $0.40 per share, for a total transaction of $125,000.00. Following the purchase, the director owned 332,500 shares in the company, valued at $133,000. The trade was a 1,562.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 20,433,650 shares of company stock valued at $8,173,460. Insiders own 5.70% of the company’s stock.

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.